Risks for MACE, Mortality Lower After Surgery for Hyperthyroidism
By Elana Gotkine HealthDay Reporter
TUESDAY, March 12, 2024 -- For patients with newly diagnosed hyperthyroidism, surgery is associated with lower risks for major adverse cardiovascular events (MACE) and all-cause mortality, according to a study published online March 4 in JAMA Network Open.
Carol Chiung-Hui Peng, M.D., from the Boston University Chobanian and Avedisian School of Medicine, and colleagues conducted a nationwide cohort study involving patients aged 20 years or older with newly diagnosed hyperthyroidism between 2011 and 2020. The risks for MACE and all-cause mortality were compared for those treated with antithyroid drugs (ATDs), radioactive iodine (RAI), or surgery.
Of the 114,062 patients with newly diagnosed hyperthyroidism, 93.9, 1.1, and 5.1 percent received ATDs alone, received RAI, and underwent surgery, respectively, during a mean follow-up of 4.4 years. The researchers found that compared with patients receiving ATDs, those undergoing surgery had a significantly lower risk for MACE, all-cause mortality, heart failure, and cardiovascular mortality (hazard ratios, 0.76, 0.53, 0.33, and 0.45, respectively). RAI was associated with lower MACE risk compared with ATDs (hazard ratio, 0.45). The treatment groups had no significant difference in risks for acute myocardial infarction or stroke.
"These findings suggest that surgery or RAI may be better options than long-term ATD treatment in patients with hyperthyroidism who are at risk of MACE," the authors write. "However, these findings should be interpreted with caution owing to the retrospective, observational nature of the study design, which precludes the evaluation of causal relationships."
Two authors report receipt of personal fees from the National Dairy Council; one disclosed ties to Merck China.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Overall Burden of CVD Remained High in United Kingdom in 2000 to 2019
THURSDAY, June 27, 2024 -- The overall burden of cardiovascular disease (CVD) remained high during 2000 to 2019 in the United Kingdom, according to a study published online June...
hs-cTnT Linked to MACE, Mortality in Rheumatoid Arthritis
THURSDAY, June 27, 2024 -- For patients with rheumatoid arthritis (RA), a detectable level of high-sensitivity cardiac troponin T (hs-cTnT) is associated with increased risk of...
Pediatric Surgical Opioid Prescribing Concentrated Among a Few Procedures
WEDNESDAY, June 26, 2024 -- Pediatric surgical opioid prescribing is concentrated among a small number of procedures, especially tonsillectomy and/or adenectomy, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.